apalutamide
apalutamide: 37 clinical trials tracked.
apalutamide evidence translation
What we can confirm
37 tracked trials
What it means
What to watch
Prepared research question
What is verified about apalutamide, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 11 study sponsors
Related indications
Clinical Trials (37)showing 10 most recent
MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer
Primary endpoint: Assess the efficacy of MRT-2359 combined with apalutamide
A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Primary endpoint: Radiographic Progression-Free Survival (rPFS)
A Randomized Trial of Apalutamide in Non-Muscle Invasive Bladder Cancer
Primary endpoint: Average Epidermal Growth Factor Receptor (EGFR) expression level
Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)
Primary endpoint: Overall survival (OS)
Double-DARE: Analysis of Doublet and Triplet Therapy With Darolutamide and Other Androgen Receptor Pathway Inhibitors in de Novo mHSPC Patients Seen in Urology Clinics in the USA
Primary endpoint: Describe baseline demographic of de novo mHSPC patients receiving darolutamide + ADT + docetaxel (triplet therapy): age
Real-world Clinical Outcomes With Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Castration-sensitive Prostate Cancer (mCSPC) in the Flatiron Health Electronic Health Records (EHR) Database
Primary endpoint: Treatment duration
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Primary endpoint: Overall Survival
ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)
Primary endpoint: Biologically active and tolerable dose range
MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer
Primary endpoint: Modified radiographic progression-free survival (mrPFS) (Groups A & B)
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
Primary endpoint: Parts 1, 2C, 3 and 4: Number of Participants With Dose Limiting Toxicity (DLT)